Bioventus Inc.
Bioventus Inc. (BVS) Financial Performance & Income Statement Overview
Review Bioventus Inc. (BVS) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Bioventus Inc. (BVS) Income Statement & Financial Overview
Explore comprehensive income reports for Bioventus Inc. BVS, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $123.88M | $153.64M | $138.96M | $151.22M |
| Cost of Revenue | $40.82M | $50.99M | $45.41M | $47.58M |
| Gross Profit | $83.06M | $100.89M | $93.55M | $103.64M |
| Gross Profit Ratio | $0.67 | $0.66 | $0.67 | $0.69 |
| R&D Expenses | $3.01M | $3.25M | $3.81M | $3.99M |
| SG&A Expenses | $73.50M | $86.61M | $81.09M | $94.78M |
| Operating Expenses | $78.19M | $94.67M | $84.90M | $133.007M |
| Total Costs & Expenses | $119.007M | $145.65M | $130.31M | $180.59M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $7.51M | $9.00M | $9.53M | $9.92M |
| Depreciation & Amortization | $11.87M | $12.40M | $12.28M | $13.09M |
| EBITDA | $15.96M | $21.63M | $16.98M | -$16.44M |
| EBITDA Ratio | $0.13 | $0.14 | $0.12 | -$0.11 |
| Operating Income | $4.87M | $7.99M | $4.07M | -$29.37M |
| Operating Income Ratio | $0.04 | $0.05 | $0.03 | -$0.19 |
| Other Income/Expenses (Net) | -$8.29M | -$7.76M | -$8.91M | -$10.08M |
| Income Before Tax | -$3.42M | $232000.00 | -$4.83M | -$39.45M |
| Income Before Tax Ratio | -$0.03 | $0.002 | -$0.03 | -$0.26 |
| Income Tax Expense | -$95000.00 | $550000.00 | $589000.00 | -$7.34M |
| Net Income | -$2.64M | -$156000.00 | -$4.82M | -$23.99M |
| Net Income Ratio | -$0.02 | -$0.001 | -$0.03 | -$0.16 |
| EPS | -$0.04 | -$0.002 | -$0.07 | -$0.37 |
| Diluted EPS | -$0.04 | -$0.002 | -$0.07 | -$0.37 |
| Weighted Avg Shares Outstanding | $66.009M | $65.45M | $65.26M | $64.06M |
| Weighted Avg Shares Outstanding (Diluted) | $66.009M | $65.45M | $65.26M | $64.06M |
Over the last four quarters, Bioventus Inc. achieved steady financial progress, growing revenue from $151.22M in Q2 2024 to $123.88M in Q1 2025. Gross profit stayed firm with margins at 67% in Q1 2025 versus 69% in Q2 2024. Operating income totaled $4.87M in Q1 2025, maintaining a 4% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $15.96M. Net income dropped to -$2.64M, with EPS at -$0.04. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan